Happy Memorial Day! Use Promo Code: HERO to save 20%

FDA Approves GW Pharma’s Epidiolex

June 26, 2018

According to a press release, the U.S. Food and Drug Administration (FDA) approved GW Pharma’s drug Epidiolex for the treatment of rare forms of epilepsy. Just a few months ago, news broke of a very encouraging FDA panel assessment, which indicated a positive outlook for the drug’s approval.

In the press release, FDA Commissioner Scott Gottlieb, M.D appeared to indicate an open willingness to explore the medical benefits of cannabis. “This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies,” says Gottlieb. “And, the FDA is committed to this kind of careful scientific research and drug development.” He went on to add:FDAlogo

Controlled clinical trials testing the safety and efficacy of a drug, along with careful review through the FDA’s drug approval process, is the most appropriate way to bring marijuana-derived treatments to patients. Because of the adequate and well-controlled clinical studies that supported this approval, prescribers can have confidence in the drug’s uniform strength and consistent delivery that support appropriate dosing needed for treating patients with these complex and serious epilepsy syndromes. We’ll continue to support rigorous scientific research on the potential medical uses of marijuana-derived products and work with product developers who are interested in bringing patients safe and effective, high quality products. But, at the same time, we are prepared to take action when we see the illegal marketing of CBD-containing products with serious, unproven medical claims. Marketing unapproved products, with uncertain dosages and formulations can keep patients from accessing appropriate, recognized therapies to treat serious and even fatal diseases.

According to the press release, the drug was studied in three randomized, double-blind, placebo-controlled clinical trials with 516 patients who have either Lennox-Gastaut syndrome or Dravet syndrome, the two rare forms of epilepsy the drug is now approved to treat. Epidiolex is an anti-epilepsy drug, taken in a syrup form, with the main active ingredient being cannabidiol (CBD), and less than 0.1 % THC.

The post FDA Approves GW Pharma’s Epidiolex appeared first on Cannabis Industry Journal.





Also in Education

Understanding CBD Oil Concentrations in Skin Care

May 26, 2019

When it comes to CBD skin care, the biggest challenge isn’t choosing between the bewildering array of products, it’s figuring […]

Continue Reading

Here’s Where to Find the Best CBD Coconut Oil for Sale

May 26, 2019

CBD and coconut oil make an excellent combination for a number of reasons, and it was perhaps only a matter […]

Continue Reading

Is Infusing Non-THC E-Liquid With THC Worth the Hassle?

May 25, 2019

As recreational cannabis and products containing its derivatives become more widely available, it might seem unnecessary to go to the […]

Continue Reading